Full Year 2025 Ipsen SA Earnings Call Transcript
Key Points
- Ipsen SA (IPSEY) reported a strong double-digit sales growth of 10.9% for 2025, driven by a 14.2% increase in their portfolio excluding Somatuline.
- The company achieved a core operating margin of 35.2% of total sales, reflecting efficient cost management.
- Ipsen SA (IPSEY) has a robust pipeline with five key milestones expected in 2026, including three pivotal readouts.
- The company maintains a solid balance sheet with no debt and €3.2 billion available for external innovation.
- Ipsen SA (IPSEY) anticipates another year of double-digit sales growth in 2026, supported by accelerated performance across the entire portfolio.
- Sales of Somatuline declined in the last quarter due to a high baseline in 2024, indicating potential challenges in maintaining growth.
- The company recognized impairment losses of about €350 million before tax, impacting their financial results.
- Ipsen SA (IPSEY) faces ongoing competitive challenges in the rare disease segment, particularly in the PIC indication.
- Currency movements had an adverse impact on the company's financial performance, translating into an 8.1% growth at current rates.
- The company anticipates a lower level of other revenue in 2026, which may impact their operating margin.
Good day and thank you for standing by. Welcome to IPSEN's conference call and webcast on full year 2025 results. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press one and one again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, David Lowe, Ibsen CEO. Please go ahead.
Thank you operator and hello everyone. I'm delighted to welcome you to our presentation this afternoon, which can also be found on IPSEN.com. I want to use the time we have together to focus on the progress IBPSEN delivered in 2025 and on the future opportunities and platforms for growth. Please turn to slide 2.
Please take note of our forward-looking statements which outline
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
